Which has preferable earnings and valuation, PODD or DXCM?

DexCom has higher revenue and earnings than Insulet. Insulet is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insulet $2.71B 3.79 $247.10M $5.35 27.69 DexCom $4.66B 7.47 $836.30M $2.53 36.50

Is PODD or DXCM more profitable?

DexCom has a net margin of 20.12% compared to Insulet's net margin of 12.29%. DexCom's return on equity of 35.94% beat Insulet's return on equity. Company Net Margins Return on Equity Return on Assets Insulet 12.29% 29.29% 13.31% DexCom 20.12% 35.94% 14.75%

Does the media refer more to PODD or DXCM?

In the previous week, Insulet had 16 more articles in the media than DexCom. MarketBeat recorded 39 mentions for Insulet and 23 mentions for DexCom. DexCom's average media sentiment score of 1.65 beat Insulet's score of 0.42 indicating that DexCom is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insulet 11 Very Positive mention(s) 1 Positive mention(s) 27 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral DexCom 22 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to GEHC or PODD?

In the previous week, Insulet had 24 more articles in the media than GE HealthCare Technologies. MarketBeat recorded 39 mentions for Insulet and 15 mentions for GE HealthCare Technologies. GE HealthCare Technologies' average media sentiment score of 0.73 beat Insulet's score of 0.42 indicating that GE HealthCare Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GE HealthCare Technologies 6 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insulet 11 Very Positive mention(s) 1 Positive mention(s) 27 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, RMD or PODD?

ResMed has higher revenue and earnings than Insulet. ResMed is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ResMed $5.65B 5.91 $1.52B $10.43 22.21 Insulet $2.71B 3.79 $247.10M $5.35 27.69

Is RMD or PODD more profitable?

ResMed has a net margin of 26.94% compared to Insulet's net margin of 12.29%. Insulet's return on equity of 29.29% beat ResMed's return on equity. Company Net Margins Return on Equity Return on Assets ResMed 26.94% 25.58% 18.89% Insulet 12.29% 29.29% 13.31%

Does the media prefer RMD or PODD?

In the previous week, Insulet had 10 more articles in the media than ResMed. MarketBeat recorded 39 mentions for Insulet and 29 mentions for ResMed. ResMed's average media sentiment score of 1.39 beat Insulet's score of 0.42 indicating that ResMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ResMed 23 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insulet 11 Very Positive mention(s) 1 Positive mention(s) 27 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate PHG or PODD?

Insulet has a consensus target price of $195.40, indicating a potential upside of 31.88%. Given Insulet's stronger consensus rating and higher probable upside, analysts clearly believe Insulet is more favorable than Koninklijke Philips. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Koninklijke Philips 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Insulet 2 Sell rating(s) 11 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.44

Does the media refer more to PHG or PODD?

In the previous week, Insulet had 37 more articles in the media than Koninklijke Philips. MarketBeat recorded 39 mentions for Insulet and 2 mentions for Koninklijke Philips. Koninklijke Philips' average media sentiment score of 1.85 beat Insulet's score of 0.42 indicating that Koninklijke Philips is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Koninklijke Philips 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Insulet 11 Very Positive mention(s) 1 Positive mention(s) 27 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, PODD or STE?

STERIS has higher revenue and earnings than Insulet. Insulet is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insulet $2.71B 3.79 $247.10M $5.35 27.69 STERIS $5.94B 3.91 $782.30M $8.18 29.08

Is PODD or STE more profitable?

STERIS has a net margin of 13.34% compared to Insulet's net margin of 12.29%. Insulet's return on equity of 29.29% beat STERIS's return on equity. Company Net Margins Return on Equity Return on Assets Insulet 12.29% 29.29% 13.31% STERIS 13.34% 14.34% 9.66%

Insulet (PODD) Competitors

$148.16 +1.29 (+0.88%)

As of 08/21/2026 04:00 PM Eastern

Compare

PODD vs. DXCM, GEHC, RMD, PHG, and STE

Should you buy Insulet stock or one of its competitors? Insulet's main competitors and comparable companies include DexCom (DXCM), GE HealthCare Technologies (GEHC), ResMed (RMD), Koninklijke Philips (PHG), and STERIS (STE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Insulet compare to DexCom?

Insulet (NASDAQ:PODD) and DexCom (NASDAQ:DXCM) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

DexCom has a net margin of 20.12% compared to Insulet's net margin of 12.29%. DexCom's return on equity of 35.94% beat Insulet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insulet	12.29%	29.29%	13.31%
DexCom	20.12%	35.94%	14.75%

97.8% of DexCom shares are held by institutional investors. 0.4% of Insulet shares are held by insiders. Comparatively, 0.3% of DexCom shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Insulet had 16 more articles in the media than DexCom. MarketBeat recorded 39 mentions for Insulet and 23 mentions for DexCom. DexCom's average media sentiment score of 1.65 beat Insulet's score of 0.42 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insulet	11 Very Positive mention(s)	1 Positive mention(s)	27 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
DexCom	22 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Insulet has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market. Comparatively, DexCom has a beta of 1.41, meaning that its share price is 41% more volatile than the broader market.

DexCom has higher revenue and earnings than Insulet. Insulet is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insulet	$2.71B	3.79	$247.10M	$5.35	27.69
DexCom	$4.66B	7.47	$836.30M	$2.53	36.50

Insulet presently has a consensus price target of $195.40, indicating a potential upside of 31.88%. DexCom has a consensus price target of $88.71, indicating a potential downside of 3.93%. Given Insulet's higher possible upside, equities analysts clearly believe Insulet is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insulet	2 Sell rating(s)	11 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.44
DexCom	1 Sell rating(s)	3 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.89

Summary

DexCom beats Insulet on 13 of the 17 factors compared between the two stocks.

How does Insulet compare to GE HealthCare Technologies?

GE HealthCare Technologies (NASDAQ:GEHC) and Insulet (NASDAQ:PODD) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

In the previous week, Insulet had 24 more articles in the media than GE HealthCare Technologies. MarketBeat recorded 39 mentions for Insulet and 15 mentions for GE HealthCare Technologies. GE HealthCare Technologies' average media sentiment score of 0.73 beat Insulet's score of 0.42 indicating that GE HealthCare Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GE HealthCare Technologies	6 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insulet	11 Very Positive mention(s)	1 Positive mention(s)	27 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

GE HealthCare Technologies currently has a consensus target price of $77.73, indicating a potential upside of 3.89%. Insulet has a consensus target price of $195.40, indicating a potential upside of 31.88%. Given Insulet's higher possible upside, analysts plainly believe Insulet is more favorable than GE HealthCare Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GE HealthCare Technologies	0 Sell rating(s)	11 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.48
Insulet	2 Sell rating(s)	11 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.44

82.1% of GE HealthCare Technologies shares are owned by institutional investors. 0.4% of GE HealthCare Technologies shares are owned by insiders. Comparatively, 0.4% of Insulet shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

GE HealthCare Technologies has higher revenue and earnings than Insulet. GE HealthCare Technologies is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GE HealthCare Technologies	$20.63B	1.64	$2.08B	$4.36	17.16
Insulet	$2.71B	3.79	$247.10M	$5.35	27.69

GE HealthCare Technologies has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market. Comparatively, Insulet has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market.

Insulet has a net margin of 12.29% compared to GE HealthCare Technologies' net margin of 9.33%. Insulet's return on equity of 29.29% beat GE HealthCare Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GE HealthCare Technologies	9.33%	20.12%	5.74%
Insulet	12.29%	29.29%	13.31%

Summary

Insulet beats GE HealthCare Technologies on 10 of the 15 factors compared between the two stocks.

How does Insulet compare to ResMed?

ResMed (NYSE:RMD) and Insulet (NASDAQ:PODD) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

ResMed currently has a consensus price target of $239.38, indicating a potential upside of 3.35%. Insulet has a consensus price target of $195.40, indicating a potential upside of 31.88%. Given Insulet's stronger consensus rating and higher probable upside, analysts clearly believe Insulet is more favorable than ResMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ResMed	0 Sell rating(s)	10 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.41
Insulet	2 Sell rating(s)	11 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.44

ResMed has a net margin of 26.94% compared to Insulet's net margin of 12.29%. Insulet's return on equity of 29.29% beat ResMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ResMed	26.94%	25.58%	18.89%
Insulet	12.29%	29.29%	13.31%

ResMed has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Insulet has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market.

In the previous week, Insulet had 10 more articles in the media than ResMed. MarketBeat recorded 39 mentions for Insulet and 29 mentions for ResMed. ResMed's average media sentiment score of 1.39 beat Insulet's score of 0.42 indicating that ResMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ResMed	23 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insulet	11 Very Positive mention(s)	1 Positive mention(s)	27 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

55.0% of ResMed shares are owned by institutional investors. 0.7% of ResMed shares are owned by company insiders. Comparatively, 0.4% of Insulet shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

ResMed has higher revenue and earnings than Insulet. ResMed is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ResMed	$5.65B	5.91	$1.52B	$10.43	22.21
Insulet	$2.71B	3.79	$247.10M	$5.35	27.69

Summary

ResMed beats Insulet on 9 of the 16 factors compared between the two stocks.

How does Insulet compare to Koninklijke Philips?

Koninklijke Philips (NYSE:PHG) and Insulet (NASDAQ:PODD) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation.

13.7% of Koninklijke Philips shares are owned by institutional investors. 0.4% of Insulet shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Insulet has a net margin of 12.29% compared to Koninklijke Philips' net margin of 6.30%. Insulet's return on equity of 29.29% beat Koninklijke Philips' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Koninklijke Philips	6.30%	14.38%	5.96%
Insulet	12.29%	29.29%	13.31%

Koninklijke Philips has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market. Comparatively, Insulet has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market.

In the previous week, Insulet had 37 more articles in the media than Koninklijke Philips. MarketBeat recorded 39 mentions for Insulet and 2 mentions for Koninklijke Philips. Koninklijke Philips' average media sentiment score of 1.85 beat Insulet's score of 0.42 indicating that Koninklijke Philips is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Koninklijke Philips	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Insulet	11 Very Positive mention(s)	1 Positive mention(s)	27 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Koninklijke Philips has higher revenue and earnings than Insulet. Koninklijke Philips is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Koninklijke Philips	$20.17B	1.34	$1.01B	$1.36	20.18
Insulet	$2.71B	3.79	$247.10M	$5.35	27.69

Insulet has a consensus target price of $195.40, indicating a potential upside of 31.88%. Given Insulet's stronger consensus rating and higher probable upside, analysts clearly believe Insulet is more favorable than Koninklijke Philips.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Koninklijke Philips	0 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Insulet	2 Sell rating(s)	11 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.44

Summary

Insulet beats Koninklijke Philips on 12 of the 16 factors compared between the two stocks.

How does Insulet compare to STERIS?

Insulet (NASDAQ:PODD) and STERIS (NYSE:STE) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk.

94.7% of STERIS shares are held by institutional investors. 0.4% of Insulet shares are held by insiders. Comparatively, 1.1% of STERIS shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Insulet currently has a consensus price target of $195.40, indicating a potential upside of 31.88%. STERIS has a consensus price target of $271.33, indicating a potential upside of 14.08%. Given Insulet's higher possible upside, equities analysts clearly believe Insulet is more favorable than STERIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insulet	2 Sell rating(s)	11 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.44
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

STERIS has a net margin of 13.34% compared to Insulet's net margin of 12.29%. Insulet's return on equity of 29.29% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insulet	12.29%	29.29%	13.31%
STERIS	13.34%	14.34%	9.66%

In the previous week, Insulet had 39 more articles in the media than STERIS. MarketBeat recorded 39 mentions for Insulet and 0 mentions for STERIS. STERIS's average media sentiment score of 1.21 beat Insulet's score of 0.42 indicating that STERIS is being referred to more favorably in the news media.

Company	Overall Sentiment
Insulet	Neutral
STERIS	Positive

STERIS has higher revenue and earnings than Insulet. Insulet is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insulet	$2.71B	3.79	$247.10M	$5.35	27.69
STERIS	$5.94B	3.91	$782.30M	$8.18	29.08

Insulet has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market. Comparatively, STERIS has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market.

Summary

STERIS beats Insulet on 10 of the 16 factors compared between the two stocks.

Get Insulet News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PODD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PODD vs. The Competition

Export

Metric	Insulet	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$10.28B	$6.02B	$7.37B	$12.85B
Dividend Yield	N/A	1.75%	2.53%	11.08%
P/E Ratio	27.69	26.67	272.60	24.24
Price / Sales	3.79	45.38	618.96	99.78
Price / Cash	23.43	33.24	78.62	53.99
Price / Book	7.22	6.23	13.05	6.20
Net Income	$247.10M	$150.07M	$3.47B	$348.59M
7 Day Performance	3.36%	0.69%	2.09%	0.08%
1 Month Performance	-6.45%	8.91%	6.64%	3.88%
1 Year Performance	-55.21%	8.07%	25.02%	16.98%

Insulet Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PODD Insulet	4.8068 of 5 stars	$148.16 +0.9%	$195.40 +31.9%	-55.2%	$10.28B	$2.71B	27.69	5,400	Trending News
DXCM DexCom	4.3199 of 5 stars	$88.76 -1.1%	$88.71 -0.1%	+12.3%	$33.87B	$4.66B	35.08	11,000	Positive News
GEHC GE HealthCare Technologies	3.6415 of 5 stars	$72.37 -1.8%	$77.73 +7.4%	-0.5%	$33.28B	$20.63B	16.60	54,000	Analyst Forecast
RMD ResMed	3.8892 of 5 stars	$220.37 -1.8%	$240.17 +9.0%	-21.1%	$32.56B	$5.65B	21.13	11,370	News Coverage Positive News Analyst Forecast
PHG Koninklijke Philips	3.1127 of 5 stars	$26.85 -1.6%	N/A	-3.1%	$26.82B	$20.17B	19.79	65,340	Positive News Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PODD) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Insulet (PODD) Competitors